Compare PHR & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHR | UROY |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.2M | 601.8M |
| IPO Year | 2019 | N/A |
| Metric | PHR | UROY |
|---|---|---|
| Price | $9.53 | $3.73 |
| Analyst Decision | Buy | |
| Analyst Count | 18 | 0 |
| Target Price | ★ $21.18 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 2.1M |
| Earning Date | 05-27-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.92 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $480,591,000.00 | N/A |
| Revenue This Year | $8.43 | $279.20 |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | ★ $220.25 | $1,584.46 |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $7.77 | $1.75 |
| 52 Week High | $32.76 | $5.52 |
| Indicator | PHR | UROY |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 50.70 |
| Support Level | $7.78 | $3.54 |
| Resistance Level | $12.68 | $4.07 |
| Average True Range (ATR) | 0.50 | 0.23 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 79.90 | 33.33 |
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.